Cargando…

Histomorphometric Analysis of 38 Giant Cell Tumors of Bone after Recurrence as Compared to Changes Following Denosumab Treatment

SIMPLE SUMMARY: Giant cell tumor of bone (GCTB) is an osteolytic tumor driven by an H3F3A-mutated mononuclear stromal cell with an accumulation of osteoclastic giant cells. Anti-RANKL antibody therapy with denosumab leads to morphological changes, and sarcomas have been described in association with...

Descripción completa

Detalles Bibliográficos
Autores principales: Arndt, Sophia, Hartmann, Wolfgang, Rókusz, András, Leinauer, Benedikt, von Baer, Alexandra, Schultheiss, Markus, Pablik, Jessica, Fritzsche, Hagen, Mogler, Carolin, Antal, Imre, Baumhoer, Daniel, Mellert, Kevin, Möller, Peter, Szendrői, Miklós, Jundt, Gernot, Barth, Thomas F. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486357/
https://www.ncbi.nlm.nih.gov/pubmed/37686526
http://dx.doi.org/10.3390/cancers15174249
_version_ 1785102987349196800
author Arndt, Sophia
Hartmann, Wolfgang
Rókusz, András
Leinauer, Benedikt
von Baer, Alexandra
Schultheiss, Markus
Pablik, Jessica
Fritzsche, Hagen
Mogler, Carolin
Antal, Imre
Baumhoer, Daniel
Mellert, Kevin
Möller, Peter
Szendrői, Miklós
Jundt, Gernot
Barth, Thomas F. E.
author_facet Arndt, Sophia
Hartmann, Wolfgang
Rókusz, András
Leinauer, Benedikt
von Baer, Alexandra
Schultheiss, Markus
Pablik, Jessica
Fritzsche, Hagen
Mogler, Carolin
Antal, Imre
Baumhoer, Daniel
Mellert, Kevin
Möller, Peter
Szendrői, Miklós
Jundt, Gernot
Barth, Thomas F. E.
author_sort Arndt, Sophia
collection PubMed
description SIMPLE SUMMARY: Giant cell tumor of bone (GCTB) is an osteolytic tumor driven by an H3F3A-mutated mononuclear stromal cell with an accumulation of osteoclastic giant cells. Anti-RANKL antibody therapy with denosumab leads to morphological changes, and sarcomas have been described in association with therapy. We compared tissue from patients with recurrence of GCTB with samples after denosumab therapy, including two cases of malignant transformation. We detected that profound changes in morphology and the immunohistochemical profile after denosumab therapy are not compatible with changes detected in the sarcomas including expression of RUNX2, SATB2, and KI-67. ABSTRACT: Giant cell tumor of bone (GCTB) is an osteolytic tumor driven by an H3F3A-mutated mononuclear cell with the accumulation of osteoclastic giant cells. We analyzed tissue from 13 patients with recurrence and 25 patients with denosumab therapy, including two cases of malignant transformation. We found a decrease in the total number of cells (p = 0.03), but not in the individual cell populations when comparing primary and recurrence. The patients treated with denosumab showed induction of osteoid formation increasing during therapy. The total number of cells was reduced (p < 0.0001) and the number of H3F3A-mutated tumor cells decreased (p = 0.0001), while the H3F3A wild-type population remained stable. The KI-67 proliferation rate dropped from 10% to 1% and Runx2- and SATB2-positive cells were reduced. The two cases of malignant transformation revealed a loss of the H3F3A-mutated cells, while the KI-67 rate increased. Changes in RUNX2 and SATB2 expression were higher in one sarcoma, while in the other RUNX2 was decreased and SATB2-positive cells were completely lost. We conclude that denosumab has a strong impact on the morphology of GCTB. KI-67, RUNX2 and SATB2 expression differed depending on the benign or malignant course of the tumor under denosumab therapy.
format Online
Article
Text
id pubmed-10486357
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104863572023-09-09 Histomorphometric Analysis of 38 Giant Cell Tumors of Bone after Recurrence as Compared to Changes Following Denosumab Treatment Arndt, Sophia Hartmann, Wolfgang Rókusz, András Leinauer, Benedikt von Baer, Alexandra Schultheiss, Markus Pablik, Jessica Fritzsche, Hagen Mogler, Carolin Antal, Imre Baumhoer, Daniel Mellert, Kevin Möller, Peter Szendrői, Miklós Jundt, Gernot Barth, Thomas F. E. Cancers (Basel) Article SIMPLE SUMMARY: Giant cell tumor of bone (GCTB) is an osteolytic tumor driven by an H3F3A-mutated mononuclear stromal cell with an accumulation of osteoclastic giant cells. Anti-RANKL antibody therapy with denosumab leads to morphological changes, and sarcomas have been described in association with therapy. We compared tissue from patients with recurrence of GCTB with samples after denosumab therapy, including two cases of malignant transformation. We detected that profound changes in morphology and the immunohistochemical profile after denosumab therapy are not compatible with changes detected in the sarcomas including expression of RUNX2, SATB2, and KI-67. ABSTRACT: Giant cell tumor of bone (GCTB) is an osteolytic tumor driven by an H3F3A-mutated mononuclear cell with the accumulation of osteoclastic giant cells. We analyzed tissue from 13 patients with recurrence and 25 patients with denosumab therapy, including two cases of malignant transformation. We found a decrease in the total number of cells (p = 0.03), but not in the individual cell populations when comparing primary and recurrence. The patients treated with denosumab showed induction of osteoid formation increasing during therapy. The total number of cells was reduced (p < 0.0001) and the number of H3F3A-mutated tumor cells decreased (p = 0.0001), while the H3F3A wild-type population remained stable. The KI-67 proliferation rate dropped from 10% to 1% and Runx2- and SATB2-positive cells were reduced. The two cases of malignant transformation revealed a loss of the H3F3A-mutated cells, while the KI-67 rate increased. Changes in RUNX2 and SATB2 expression were higher in one sarcoma, while in the other RUNX2 was decreased and SATB2-positive cells were completely lost. We conclude that denosumab has a strong impact on the morphology of GCTB. KI-67, RUNX2 and SATB2 expression differed depending on the benign or malignant course of the tumor under denosumab therapy. MDPI 2023-08-24 /pmc/articles/PMC10486357/ /pubmed/37686526 http://dx.doi.org/10.3390/cancers15174249 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Arndt, Sophia
Hartmann, Wolfgang
Rókusz, András
Leinauer, Benedikt
von Baer, Alexandra
Schultheiss, Markus
Pablik, Jessica
Fritzsche, Hagen
Mogler, Carolin
Antal, Imre
Baumhoer, Daniel
Mellert, Kevin
Möller, Peter
Szendrői, Miklós
Jundt, Gernot
Barth, Thomas F. E.
Histomorphometric Analysis of 38 Giant Cell Tumors of Bone after Recurrence as Compared to Changes Following Denosumab Treatment
title Histomorphometric Analysis of 38 Giant Cell Tumors of Bone after Recurrence as Compared to Changes Following Denosumab Treatment
title_full Histomorphometric Analysis of 38 Giant Cell Tumors of Bone after Recurrence as Compared to Changes Following Denosumab Treatment
title_fullStr Histomorphometric Analysis of 38 Giant Cell Tumors of Bone after Recurrence as Compared to Changes Following Denosumab Treatment
title_full_unstemmed Histomorphometric Analysis of 38 Giant Cell Tumors of Bone after Recurrence as Compared to Changes Following Denosumab Treatment
title_short Histomorphometric Analysis of 38 Giant Cell Tumors of Bone after Recurrence as Compared to Changes Following Denosumab Treatment
title_sort histomorphometric analysis of 38 giant cell tumors of bone after recurrence as compared to changes following denosumab treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486357/
https://www.ncbi.nlm.nih.gov/pubmed/37686526
http://dx.doi.org/10.3390/cancers15174249
work_keys_str_mv AT arndtsophia histomorphometricanalysisof38giantcelltumorsofboneafterrecurrenceascomparedtochangesfollowingdenosumabtreatment
AT hartmannwolfgang histomorphometricanalysisof38giantcelltumorsofboneafterrecurrenceascomparedtochangesfollowingdenosumabtreatment
AT rokuszandras histomorphometricanalysisof38giantcelltumorsofboneafterrecurrenceascomparedtochangesfollowingdenosumabtreatment
AT leinauerbenedikt histomorphometricanalysisof38giantcelltumorsofboneafterrecurrenceascomparedtochangesfollowingdenosumabtreatment
AT vonbaeralexandra histomorphometricanalysisof38giantcelltumorsofboneafterrecurrenceascomparedtochangesfollowingdenosumabtreatment
AT schultheissmarkus histomorphometricanalysisof38giantcelltumorsofboneafterrecurrenceascomparedtochangesfollowingdenosumabtreatment
AT pablikjessica histomorphometricanalysisof38giantcelltumorsofboneafterrecurrenceascomparedtochangesfollowingdenosumabtreatment
AT fritzschehagen histomorphometricanalysisof38giantcelltumorsofboneafterrecurrenceascomparedtochangesfollowingdenosumabtreatment
AT moglercarolin histomorphometricanalysisof38giantcelltumorsofboneafterrecurrenceascomparedtochangesfollowingdenosumabtreatment
AT antalimre histomorphometricanalysisof38giantcelltumorsofboneafterrecurrenceascomparedtochangesfollowingdenosumabtreatment
AT baumhoerdaniel histomorphometricanalysisof38giantcelltumorsofboneafterrecurrenceascomparedtochangesfollowingdenosumabtreatment
AT mellertkevin histomorphometricanalysisof38giantcelltumorsofboneafterrecurrenceascomparedtochangesfollowingdenosumabtreatment
AT mollerpeter histomorphometricanalysisof38giantcelltumorsofboneafterrecurrenceascomparedtochangesfollowingdenosumabtreatment
AT szendroimiklos histomorphometricanalysisof38giantcelltumorsofboneafterrecurrenceascomparedtochangesfollowingdenosumabtreatment
AT jundtgernot histomorphometricanalysisof38giantcelltumorsofboneafterrecurrenceascomparedtochangesfollowingdenosumabtreatment
AT barththomasfe histomorphometricanalysisof38giantcelltumorsofboneafterrecurrenceascomparedtochangesfollowingdenosumabtreatment